16:25:27 EDT Tue 09 Jun 2026
Enter Symbol
or Name
USA
CA



Q:UTHR - UNITED THERAPEUTICS CORP - https://www.unither.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
UTHR - Q2.0522.55·555.000.2553.14+8.451.6325.6178,58310,314550.89  554.48  544.00609.35  272.17516:06:26May 2715 min RT 2¢

Recent Trades - Last 10 of 10314
Time ETExPriceChangeVolume
16:06:26Q553.148.458
16:04:52Q553.148.451
16:04:51Q553.148.451
16:04:50Q553.148.451
16:04:45Q553.148.451
16:04:38Q553.148.451
16:04:35Q553.148.451
16:04:19Q553.148.451
16:04:16Q553.148.451
16:04:16Q553.148.451

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-05-27 07:00U:UTHRNews ReleaseUnited Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference
2026-05-18 16:15U:UTHRNews ReleaseUnited Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026
2026-05-17 14:15U:UTHRNews ReleaseUnited Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026
2026-05-15 18:00U:UTHRNews ReleaseUnited Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial
2026-05-12 07:00U:UTHRNews ReleaseUnited Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference
2026-05-11 06:30U:UTHRNews ReleaseUnited Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026
2026-05-06 06:30U:UTHRNews ReleaseUnited Therapeutics Corporation Reports First Quarter 2026 Financial Results
2026-05-06 06:30U:UTHRNews ReleaseMannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
2026-04-29 07:00U:UTHRNews ReleaseUnited Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors
2026-04-22 07:00U:UTHRNews ReleaseUnited Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026
2026-04-20 06:30U:UTHRNews ReleaseUnited Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026
2026-04-08 07:00U:UTHRNews ReleaseUnited Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP(TM) for Treatment of Acute Liver Failure
2026-03-30 07:00U:UTHRNews ReleaseUnited Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso(TM) Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2
2026-03-09 07:00U:UTHRNews ReleaseUnited Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program
2026-03-03 07:00U:UTHRNews ReleaseUnited Therapeutics Corporation to Present at the Leerink Global Healthcare Conference
2026-03-02 06:30U:UTHRNews ReleaseUnited Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy
2026-02-25 06:30U:UTHRNews ReleaseUnited Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
2026-02-23 07:00U:UTHRNews ReleaseUnited Therapeutics Corporation to Present at the TD Cowen 46th Annual Health Care Conference
2026-02-11 07:00U:UTHRNews ReleaseUnited Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026
2026-01-26 07:00U:UTHRNews ReleaseUnited Therapeutics Announces Positive Results from Phase 1 Study of miroliverELAP(TM) in Patients with Acute Liver Failure